Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanidatamab - BeiGene/Jazz Pharmaceuticals Inc/Zymeworks

Next Previous
X
Search
Drug Profile

Zanidatamab - BeiGene/Jazz Pharmaceuticals Inc/Zymeworks

Alternative Names: JZP-598; Zani - BeiGene/Jazz Pharmaceuticals Inc/Zymeworks; ZW 25

Latest Information Update: 23 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zymeworks
  • Developer ALX Oncology; BeiGene; Canadian Cancer Trials Group; Jazz Pharmaceuticals Inc; Zymeworks
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; ERBB 2 receptor antagonists; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Biliary cancer; Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Biliary cancer
  • Phase III Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Oesophageal cancer
  • Phase II Endometrial cancer; Gastrointestinal cancer
  • Phase I/II Solid tumours
  • No development reported Ovarian cancer

Most Recent Events

  • 16 Sep 2024 Updated efficacy data from a phase II trial in Gastroesophageal adenocarcinoma released by Jazz Pharmaceuticals
  • 31 Jul 2024 EMA validates MAA for Biliary tract cancer (Second-line therapy) in European Union
  • 30 Jul 2024 Phase-III clinical trials in HER2-positive-breast-cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06435429) (EudraCT2023-508960-31-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top